DM
Deerfield Management Portfolio holdings
AUM
$5.51B
This Quarter Return
-3.27%
1 Year Return
+12.76%
3 Year Return
+152.98%
5 Year Return
+204.91%
10 Year Return
+993.1%
AUM
$6.01B
AUM Growth
+$6.01B
(+4.6%)
Cap. Flow
+$36.4M
Cap. Flow
% of AUM
0.61%
Top 10 Holdings %
Top 10 Hldgs %
51.52%
Holding
592
New
224
Increased
125
Reduced
43
Closed
159
Top Buys
| 1 |
WAY
Waystar Holding Corp
WAY
|
$106M |
| 2 |
Gilead Sciences
GILD
|
$102M |
| 3 |
CVS Health
CVS
|
$57.6M |
| 4 |
Baxter International
BAX
|
$52.6M |
| 5 |
Cullinan Oncology
CGEM
|
$37.4M |
Top Sells
Sector Composition
| 1 | Healthcare | 83.29% |
| 2 | Industrials | 0.67% |
| 3 | Technology | 0.57% |
| 4 | Financials | 0.44% |
| 5 | Consumer Discretionary | 0.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Nuvalent
NUVL
$5.52B
| $1.52B | 25.23% | 19,991,024 | – | – |
|
2
Viatris
VTRS
$12.3B
| $227M | 3.78% | 21,395,496 +444 | +0% | +$4.72K |
|
3
Centene
CNC
$14.3B
| $176M | 2.92% | 2,650,122 +269,078 | +11% | +$17.8M |
|
4
Merus
MRUS
$4.98B
| $163M | 2.71% | 2,749,401 +100,000 | +4% | +$5.92M |
|
5
Larimar Therapeutics
LRMR
$310M
| $154M | 2.56% | 21,231,974 | – | – |
|
6
Catalyst Pharmaceutical
CPRX
$2.52B
| $141M | 2.35% | 9,127,305 -3,512 | -0% | -$54.4K |
|
7
AdaptHealth
AHCO
$1.28B
| $133M | 2.21% | 13,257,940 | – | – |
|
8
Revolution Medicines
RVMD
$7.1B
| $120M | 2% | 3,090,073 | – | – |
|
9
Surgery Partners
SGRY
$2.91B
| $112M | 1.86% | 4,707,287 +1,520,484 | +48% | +$36.2M |
|
10
Kura Oncology
KURA
$686M
| $111M | 1.85% | 5,411,571 | – | – |
|
11
Oscar Health
OSCR
$4.31B
| $110M | 1.83% | 6,959,787 -2,413,310 | -26% | -$38.2M |
|
12
Brookdale Senior Living
BKD
$1.83B
| $107M | 1.77% | 15,612,264 | – | – |
|
|
WAY
13
Waystar Holding Corp
WAY
$6.6B
| $106M | 1.77% | +4,952,004 | New | +$106M |
|
|
14
Gilead Sciences
GILD
$140B
| $102M | 1.7% | +1,491,000 | New | +$102M |
|
15
Neurocrine Biosciences
NBIX
$13.8B
| $95.1M | 1.58% | 691,004 | – | – |
|
16
ARS Pharmaceuticals
SPRY
$1.15B
| $94.3M | 1.57% | 11,077,927 | – | – |
|
17
Owens & Minor
OMI
$378M
| $86M | 1.43% | 6,371,440 +1,493,852 | +31% | +$20.2M |
|
18
Alignment Healthcare
ALHC
$3.24B
| $85.2M | 1.42% | 10,901,485 +2,630,788 | +32% | +$20.6M |
|
19
IDEAYA Biosciences
IDYA
$2.15B
| $73.6M | 1.23% | 2,097,113 -533,179 | -20% | -$18.7M |
|
20
HilleVax
HLVX
$105M
| $57.9M | 0.96% | 4,004,231 | – | – |
|
|
21
CVS Health
CVS
$92.8B
| $57.6M | 0.96% | +975,000 | New | +$57.6M |
|
|
22
Cullinan Oncology
CGEM
$445M
| $57.2M | 0.95% | 3,280,237 +2,141,706 | +188% | +$37.4M |
|
|
23
Baxter International
BAX
$12.7B
| $52.8M | 0.88% | 1,577,647 +1,571,506 | +25,590% | +$52.6M |
|
24
Edgewise Therapeutics
EWTX
$1.51B
| $51.8M | 0.86% | 2,874,586 | – | – |
|
25
BioCryst Pharmaceuticals
BCRX
$1.74B
| $50.3M | 0.84% | 8,135,804 +3,140,804 | +63% | +$19.4M |
|